Cargando…

Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model

Cholangiocarcinoma (CCA) is a malignant tumor with aggressive biological behavior. Immune checkpoints such as cytotoxic T-lymphocyte antigen 4 (CTLA4) and antiprogrammed death 1 (PD-1) are critical immune-checkpoint molecules that repress T-cell activation. The DNA vaccine potential against CTLA4 an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Yi-Ru, Wu, Chiao-En, Chen, Ming-Huang, Huang, Wen-Kuan, Shih, Hsuan-Jen, Lan, Keng-Li, Yeh, Chun-Nan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712087/ https://www.ncbi.nlm.nih.gov/pubmed/33255375 http://dx.doi.org/10.3390/vaccines8040703

Ejemplares similares

Chimeric immune checkpoint protein vaccines inhibit the tumorigenesis and growth of rat cholangiocarcinoma
por: Pan, Yi-Ru, et al.
Publicado: (2022)

Chromosomal Instability May Not Be a Predictor for Immune Checkpoint Inhibitors from a Comprehensive Bioinformatics Analysis
por: Wu, Chiao-En, et al.
Publicado: (2020)

Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation
por: Pan, Yi-Ru, et al.
Publicado: (2023)

The Emerging Role of MicroRNAs in Regulating the Drug Response of Cholangiocarcinoma
por: Huang, Wen-Kuan, et al.
Publicado: (2020)

Marked Response to Larotrectinib in Pelvic Spindle Cell Sarcoma With Concurrent TPM3-NTRK1 Fusion and CDK4/MDM2 Amplification: A Case Report
por: Huang, Wen-Kuan, et al.
Publicado: (2023)

p53 as a biomarker and potential target in gastrointestinal stromal tumors
por: Wu, Chiao-En, et al.
Publicado: (2022)

ATM Inhibitor Suppresses Gemcitabine-Resistant BTC Growth in a Polymerase θ Deficiency-Dependent Manner
por: Pan, Yi-Ru, et al.
Publicado: (2020)

Establishment of a novel gene panel as a biomarker of immune checkpoint inhibitor response
por: Pan, Yi‐Ru, et al.
Publicado: (2020)

Globo H Is a Promising Theranostic Marker for Intrahepatic Cholangiocarcinoma
por: Hung, Tsai‐Hsien, et al.
Publicado: (2021)

Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers
por: Wu, Chiao-En, et al.
Publicado: (2020)

WIP1 Inhibition by GSK2830371 Potentiates HDM201 through Enhanced p53 Phosphorylation and Activation in Liver Adenocarcinoma Cells
por: Wu, Chiao-En, et al.
Publicado: (2021)

A Nomogram Predicting Progression Free Survival in Patients with Gastrointestinal Stromal Tumor Receiving Sunitinib: Incorporating Pre-Treatment and Post-Treatment Parameters
por: Chang, Yau-Ren, et al.
Publicado: (2021)

Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway
por: Chung, Shin-Yi, et al.
Publicado: (2021)

Genomic and tumour microenvironmental biomarkers of immune checkpoint inhibitor response in advanced Taiwanese melanoma
por: Chang, John Wen‐Cheng, et al.
Publicado: (2023)

Precision Medicine in Cholangiocarcinoma: Past, Present, and Future
por: Cheng, Chi-Yuan, et al.
Publicado: (2022)

PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
por: Tan, Kien Thiam, et al.
Publicado: (2020)

Peritumoral SPARC expression and patient outcome with resectable intrahepatic cholangiocarcinoma
por: Cheng, Chi-Tung, et al.
Publicado: (2015)

Omics-Based Platforms: Current Status and Potential Use for Cholangiocarcinoma
por: Chang, Yu-Chan, et al.
Publicado: (2020)

Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges
por: Huang, Wen-Kuan, et al.
Publicado: (2022)

Clinical effect of a positive surgical margin after hepatectomy on survival of patients with intrahepatic cholangiocarcinoma
por: Yeh, Chun-Nan, et al.
Publicado: (2014)

Comprehensive analysis of DNA methylation and gene expression profiles in cholangiocarcinoma
por: Zhang, Cheng, et al.
Publicado: (2019)

Serological responses triggered by different SARS-CoV-2 vaccines against SARS-CoV-2 variants in Taiwan
por: Chao, Chiao-Hsuan, et al.
Publicado: (2022)

Application of Immune Checkpoint Inhibitors in the Treatment of Cholangiocarcinoma
por: Zeng, Fan-li, et al.
Publicado: (2021)

Cutting Edge Research for Exploration of Biomolecules for Gemcitabine-Based Chemo-Resistant Advanced Bile Duct Cancer: From Basic Study to Clinical Trial
por: Wu, Chiao-En, et al.
Publicado: (2021)

Reappraisal of the Therapeutic Role of Celecoxib in Cholangiocarcinoma
por: Yeh, Chun-Nan, et al.
Publicado: (2013)

Combined Inhibition of Smoothened and the DNA Damage Checkpoint WEE1 Exerts Antitumor Activity in Cholangiocarcinoma
por: Anichini, Giulia, et al.
Publicado: (2023)

MART-10 represses cholangiocarcinoma cell growth and high vitamin D receptor expression indicates better prognosis for cholangiocarcinoma
por: Chiang, Kun-Chun, et al.
Publicado: (2017)

Comprehensive Multiple Molecular Profile of Epithelial Mesenchymal Transition in Intrahepatic Cholangiocarcinoma Patients
por: Huang, Xiao-Yong, et al.
Publicado: (2014)

Establishment of a Pretreatment Nomogram to Predict the 6-Month Mortality Rate of Patients with Advanced Biliary Tract Cancers Undergoing Gemcitabine-Based Chemotherapy
por: Wu, Chiao-En, et al.
Publicado: (2021)

Response to Brigatinib Targeted Therapy in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 19 Deletion, T790M, and cis-C797S Triple Mutations: A Case Report
por: Chen, Zi-Wei, et al.
Publicado: (2022)

Interferon α-inducible protein 27 is an oncogene and highly expressed in cholangiocarcinoma patients with poor survival
por: Chiang, Kun-Chun, et al.
Publicado: (2019)

Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma
por: Chen, Ming-Huang, et al.
Publicado: (2015)

Comprehensive genomic profile of cholangiocarcinomas in China
por: Tian, Weijun, et al.
Publicado: (2020)

Expression of Checkpoint Molecules in the Tumor Microenvironment of Intrahepatic Cholangiocarcinoma: Implications for Immune Checkpoint Blockade Therapy
por: Heij, Lara, et al.
Publicado: (2023)

Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker
por: Chiang, Kun-Chun, et al.
Publicado: (2016)

Immune Checkpoint Inhibitors for Advanced Melanoma: Experience at a Single Institution in Taiwan
por: Wu, Chiao-En, et al.
Publicado: (2020)

Hepatectomy or/with Metastatectomy for Recurrent Intrahepatic Cholangiocarcinoma: Of Promise for Selected Patients
por: Tsai, Chun-Yi, et al.
Publicado: (2022)

Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study
por: Cao, Lu, et al.
Publicado: (2021)

Characterization of intrahepatic cholangiocarcinoma after curative resection: outcome, prognostic factor, and recurrence
por: Chan, Kun-Ming, et al.
Publicado: (2018)

Regorafenib inhibits epithelial-mesenchymal transition and suppresses cholangiocarcinoma metastasis via YAP1-AREG axis
por: Chang, Yu-Chan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ths6u13e4boapa9r97rgb8g7h2